Menu

StemExpress expands into clinical market

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

Aug 23, 2018
StemExpress

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

The new product line features Clinical Grade Non-Transfusable Bone Marrow, Leukopaks®, Mobilized Leukopaks,® and Primary Cells. Soon to follow will be Transfusable Grade Clinical products. 

Currently, with intercontinental staff and four locations nationwide, StemExpress facilities follow and comply with strict CFR 1271 FDA guidelines regarding the production, processing, and management of tissue-based cellular products to ensure overall quality and compliance, which is paramount to the success of the researchers and clinicians StemExpress supports. Through IRB-approved collection processes and protocols and with an ISO certified cGMP compliant cell manufacturing facility, the new Clinical Grade Non-Transfusable products will support pharmaceutical, biotechnology, medical device, and academic institutions that are striving to develop therapies, cures, and answers to diseases that affect all people.


July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.